India’s pharmaceutical and healthcare industry experienced strong deal activity in Q3 CY25, noting 72 deals valued at Rs. 30,902 crore (US$ 3.5 billion), as per Grant Thornton Bharat’s Dealtracker. This comprised three Initial Public Offerings (IPOs) worth Rs. 3,779 crore (US$ 428 million) and a Qualified Institutional Placement (QIP) valued at Rs. 777 crores (US$ 88 million). Apart from public market transactions, private agreements made up Rs. 26,487 crore (US$ 3 billion) through 68 deals, indicating revitalized investor trust. The increase was fueled by seven significant agreements totaling Rs. 22,955 crore (US$ 2.6 billion), highlighting the sector’s robust fundamentals and investor interest in growth, innovation, and consolidation within pharmaceutical, biotech, and hospital areas. The notable agreement was Torrent Pharma’s Rs. Acquisition of a 46% stake in JB Chemicals & Pharmaceuticals for 12,361 crore (US$ 1.4 billion), enhancing its footprint in chronic care and rapidly growing therapeutic fields. Mergers and acquisitions (M&A) transactions increased significantly, reaching 36 deals valued at Rs. 22,073 crore (US$ 2.5 billion), reflecting a 57% rise in volume compared to the last quarter. Private equity (PE) transactions totaled 32, worth Rs. 3,752 crore (US$ 425 million), as investors favor opportunities in health technology, wellness, and pharmaceutical services during the early and mid-stages. The recovery underscores increasing confidence in India's life sciences sector, fueled by consolidation, skill development, and innovation-driven expansion.